LXEO
Lexeo Therapeutics, Inc. Common Stock
There isn't enough reported data to score LXEO yet.
LXEO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
LXEO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LXEO PE Valuation
LXEO has no meaningful PE right now: it lost money over the past year.
LXEO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect LXEO's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
LXEO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.22 | +$2.05 |
| Q1 2026 | -$1.52 | +$1.79 |
| Q4 2025 | -$2.26 | +$0.83 |
LXEO is still losing money, but far less than before: $1.22 per share over the past year, against $3.31 at its worst in early 2025.
LXEO Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2022 | -3292% | N/A |
| Q2 2022 | -41381% | N/A |
| Q1 2022 | -14634% | N/A |
LXEO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$20.1M | +$8.2M |
| Q3 2025 | -$29.8M | -$11.9M |
| Q4 2024 | -$28.3M | -$14.3M |
| Q2 2024 | -$20.4M | -$7.1M |
| Q1 2024 | -$15.1M | +$3.3M |
| Q4 2023 | -$14.1M | +$2.7M |
| Q2 2023 | -$13.2M | -$2M |
| Q1 2023 | -$18.4M | -$3.1M |
LXEO has burned cash in almost every quarter: −$89M over the past year, against −$82M the year before.
LXEO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.5% | +4.4M shares |
| 1 year | +159% | +52.5M shares |
LXEO has 86M diluted shares, up 159% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
LXEO Net Leverage
LXEO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LXEO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.8 | Neutral |
| Stochastic | 15.0 | Oversold |
LXEO's weekly RSI is 34 (neutral) and its Stochastic is 15 (oversold).
LXEO PE vs Healthcare Sector
LXEO has no meaningful PE right now: it lost money over the past year.
LXEO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.06 | 4.9% below |
| 20 week MA | $4.01 | 27% below |
| 50 week MA | $5.67 | 49% below |
| 100 week MA | $5.41 | 46% below |
LXEO is in a downtrend: it's below all four of its weekly moving averages, and 46% below its 100-week average.
LXEO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $10.1 | $13.4 | +34% |
| 2024 | $13.4 | $6.78 | -49% |
| 2025 | $6.78 | $10.3 | +51% |
| 2026 YTD | $10.3 | $2.91 | -72% |
LXEO is down 72% so far in 2026, after finishing higher in two of the previous three years.